MindWalk Signs Multi-Year Antibody Deal With Teva Australia
The agreement applies MindWalk's AI-driven biological context platform to antibody discovery and design optimisation.
Updated on Nov. 5, 2026 in Biotech
MindWalk has entered into a multi-year agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology. The companies have worked together since 2018, and the financial details of the agreement have not been disclosed.
Why it matters
The deal shows how biological context platforms are being used to inform decisions during early drug development in Australia. Its reliance on AI-assisted analysis reflects a broader push to organise large volumes of biological data for research teams.
The ReefIQ platform incorporates 660 million biological patterns and 25 billion relationships, built over 20 years of data curation. The financial terms of the agreement have not been disclosed, and no results from the antibody work have been reported.
The players
MindWalk
MindWalk is a life sciences technology company that develops AI-driven biological data platforms, including the ReefIQ and LensAI systems.
Teva Pharmaceuticals Australia
Teva Pharmaceuticals Australia is the Australian arm of the global generic and specialty drug manufacturer Teva Pharmaceutical Industries.
The details
Under the agreement, Teva Australia will use MindWalk's ReefIQ platform, which connects genetic sequences, molecular structures, assay results, scientific literature and research programme records. The platform is powered by MindWalk's HYFT technology and can be paired with selected analytical capabilities from its LensAI platform.
Timeline
2018: MindWalk and Teva began working together.
5 November 2026: MindWalk announced the multi-year Teva Australia agreement.
The Tech Race
The deal extends MindWalk's HYFT technology, which underpins its ReefIQ platform, into applied antibody discovery with a major drugmaker. It reflects a wider push by life sciences firms to use AI-driven biological data systems to speed up early drug development.
The deal does not change anything for consumers directly, as no products have been announced. Its practical effect is limited to research teams using the ReefIQ platform during antibody discovery work.
The takeaway
Partnerships like this show how AI-assisted biological data platforms are becoming part of routine drug discovery work in Australia. Readers following biotech should watch for disclosed results from the antibody programme.
Further reading
For more on the sector, explore Biotech coverage.
Source note: This article includes information reported by Pharmafocusasia.
